Actinium Pharmaceuticals, Inc.
ATNM· NYSE
ATNMActinium Pharmaceuticals, Inc.
Filed Oct 23, 2020 · 10-Q · 23 days after period end · 0001213900-20-033053
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Net Income | -$5.54M | -$6.60M | -$6.15M | -$6.32M |
| EPS Diluted | -$0.36 | -$1.21 | -$0.06 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
ended Sep 30, 2020 · filed Oct 23, 2020 · 23 d after period end
